Last reviewed · How we verify
NCT05454254
Effect of Muscle Strengthening Training in Adults with Fontan Circulation
NA trial testing Individualised muscle strengthening exercise training protocol. in Congenital Heart Disease in 20 participants. Completed in 30 November 2023.
30 November 2023
Quick facts
| Lead sponsor | Umeå University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 15 August 2022 |
| Primary completion | 30 November 2023 |
| Estimated completion | 30 November 2023 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Individualised muscle strengthening exercise training protocol.
Conditions studied
- Congenital Heart Disease — all drugs for Congenital Heart Disease →
- Univentricular Heart — all drugs for Univentricular Heart →
Sponsor
Umeå University
Who can join
18 and older, any sex, with Congenital Heart Disease or Univentricular Heart. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim: to evaluate the effect of muscle strengthening exercise training in adults with Fontan circulation compared to healthy controls. Hypothesis: adults with Fontan circulation have a relatively lower effect of muscle strengthening exercise training compared to healthy controls.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Positive effects of strength training on dynamic muscle function in adults with Fontan circulation: a pilot study.
Wikner A, Rinnström D, Johansson K, Bergman F, et al · · 2025 · PMID 41424146 · DOI 10.1017/s1047951125110457
Verify or expand the search:
- PubMed search for NCT05454254
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Congenital Heart Disease
Currently open trials in the same condition.
- NCT07193719 — Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children · Phase 1, PHASE2 · recruiting
- NCT07023367 — Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents · NA · recruiting
- NCT06833320 — Propranolol Treatment for Postoperative Chylothorax · Phase 1, PHASE2 · recruiting
- NCT06668389 — Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary · Phase 4 · recruiting
- NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting
Other Umeå University trials
Trials by the same sponsor.
- NCT07407946 — Blended Trauma-Focused Cognitive Behavioral Therapy With Compassion · NA · recruiting
- NCT07346820 — VDJ-recombination of the B-cell Receptor Following Hematopoietic Stem Cell Transplantation · not yet recruiting
- NCT07417358 — Single-Stapled Technique for Colorectal Anastomosis · recruiting
- NCT07316426 — Preoptimisation in Ventral Hernia Surgery · NA · recruiting
- NCT07170722 — Sub-threshold DRG Stimulation vs Sham in Established Responders · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05454254 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Umeå University
- Last refreshed: 12 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05454254.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing